Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search

Invention Type

Information Technology/Software
Medical Device
Research Tool

Research Area

Allergy/Respiratory/Pulmonary Disease
Degenerative Disease
Genetic Disease
Health Care Management
Infectious Disease
Internal Medicine
Metabolic Disease
Personalized Medicine
Psychiatric Disease
Regenerative Medicine
Stem Cell
Surgery/Wound Healing
CMCC 2936

Novel mechanism and compound for the treatment of metastatic cancers

Inventors: Bruce Zetter, Lijun Sun

Invention Types: Therapeutics

Research Areas: Oncology/Hematology


For More Information Contact:  Ives, Catherine L.


Invention Description:

While treatment regimens for non-metastatic cancers have improved dramatically in recent history, treatment of metastatic cancers remains difficult and expensive. Five year survival rates for patients with metastatic cancer are very low, and current treatment protocols have a low success rate. Current paradigms involve the use of specific, systemic classes of drugs (e.g. androgen deprivation therapy for the treatment of recurrent prostate cancer) until resistance develops, followed by non-specific drugs which target rapidly dividing cells, such as paclitaxel or cisplatin. These approaches may extend life by 2-5 years, depending on the specific cancer and treatment regimen, but complete remission is rare. Additionally, these drugs can cause severe cytotoxic effects in healthy tissue.|

Dr. Zetter’s and Dr. Sun’s teams have identified a novel therapeutic compound, OBD9, which can selectively impair highly aggressive, metastatic tumor cells through an unprecedented and novel biological mechanism, suggesting the potential for its use in cancers resistant to other chemotherapeutics. This potent anti- proliferative and pro-apoptotic activity was demonstrated on prostate and lung cancer cells while showing little or no toxicity to normal human epithelial cells. OBD-9 is active at low micromolar concentrations, allowing the compound high potency in addition to its apparent specificity for cancer cells. Additionally, OBD9 has been shown to be effective in combination therapies with other chemotherapeutics such as cisplatin, allowing it to enhance the efficacy of existing treatment regimens. OBD9’s distinct mechanism of action, high specificity for cancer cells, and strong anti-cancer effects make it an exciting potential therapeutic for the treatment of aggressive cancers and those resistant to currently available treatments.


• Treatment of highly aggressive, metastatic cancers such as prostate, lung, breast, colon, and pancreas

• Novel mechanism of action allows for use in highly resistant cancers or in combination therapies with platinum-based drugs or immunotherapy regimens

Competitive Advantages:

• Very high efficacy and low cytotoxicity compared to other generalized chemotherapeutics used to treat metastatic cancers

• High solubility allows for oral or intravenous administration

Business Opportunity:

Sponsored research or exclusive license

Key Publications: Cheong JE, Zaffagni M, Chung I, et al. Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. Eur J Med Chem. 2018 Jan 20;114.

Related Publications: Published PCT application: WO 2010/135534

IPStatus: Pat. Pend.